Newsroom

Math Magic has officially launched Hitem3D, the world’s first AI-powered tool for 3D content creation that supports ultra-high-resolution models up to 1536^3. Users can upload a single image to instantly generate detailed 3D models, complete with texture support and downloads in multiple file formats.

By comparison, most similar tools worldwide currently offer a maximum resolution of only 1024^3. Thanks to Math Magic’s proprietary algorithms and technical breakthroughs, Hitem3D can deliver up to 1536^3 resolution. “This seemingly small difference is actually like upgrading from a GIF to an HD video,” commented an industry researcher.

According to Bo Zhang, product lead at Hitem3D, the tool helps designers without 3D modeling skills quickly turn creative ideas into high-precision models that meet production requirements. “Complex models like mecha, which used to take a senior modeler four to five working days, can now be generated by Hitem3D in under three minutes with hand-crafted detail,” Zhang said.

Future plans include adding retopology, multi-view generation, and 3D part segmentation to further reduce creation barriers and improve efficiency.

Previously, similar tools could only generate lower-resolution models because existing 3D generation techniques lost critical data during processing, leaving rough shapes and thin details. Users then had to spend significant time refining models to restore detail. Hitem3D’s ultra-high-resolution output brings WYSIWYG (what you see is what you get) to AI 3D creation.

“We pioneered direct 1536^3 resolution generation from an image, allowing unprecedented restoration of fine and micro structures. For example, if you upload a macro photo of an ant, Hitem3D can even capture the tiny bristles on its legs,” Zhang said.

Math Magic designed a unique sparse convolutional network and fully symmetric 3D VAE architecture, eliminating potential modal conversion errors. Compared to conventional models, reconstruction error (Chamfer distance) is reduced by 40%. Sparse computation lowers FLOPs by 50%, cutting training and inference costs while ensuring high-quality latent space representation for production models.

On platforms like YouTube and X, many 3D creators shared positive reviews, praising its high accuracy and fine structural reproduction. Several 3D artists reported over 90% efficiency improvements in the first modeling stage, giving digital models more realistic micro-level texture and unlocking new productivity across markets such as 3D printing, product and industrial design, game development, and film production.

For more information, visit Hitem3D's website or watch the overview video.

The Stop Gas Station Heroin coalition reviewed the beagle study commissioned by CBD American Shaman, a Missouri-based company that reports generating the majority of its revenue from the sale of “7” products in over 200 retail locations, to evaluate the effects of escalating oral doses of their formulations of 7 (semi-synthetic 7-hydroxymitragynine), and Pseudo (semi-synthetic mitragynine pseudoindoxyl).

Commissioned to support an Investigational New Drug (IND) submission, the study’s clear conflicts of interest are as alarming as its findings. Consider that CBD American Shaman, the sponsor of the research, has falsely marketed and sold these products as dietary supplements since 2022. Moreover, the study was released by the Holistic Alternative Recovery Trust (HART), an advocacy group comprised of members with a vested interest in 7-OH products.

This study raises serious concerns about the safety of 7 and Pseudo products, especially with regard to CBD American Shaman’s marketed “serving size” of 7.5 mg per serving, or half a tablet. More concerning is that in reality users consume significantly greater amounts of these products, and misuse risks include tolerance and addiction.

Critically, the study’s findings suggest that doses of more than 0.3 mg exceed a conservative threshold for human safety. This figure is based on adverse effects observed in dogs at 10 mg doses, scaled to a human-equivalent dose using FDA-recommended methods.

In other words, CBD American Shaman’s marketed serving size is more than 25 times greater than what could be considered reasonably safe based on the study’s own preclinical data, and many more times greater if measured against normal consumption of these products.

Lastly, what HART is ignoring, irrespective of the science they put forward, is that 7 and Pseudo have been chemically formulated and put into the market with the intent to cure, treat and mitigate disease; that is in relation to chronic pain, and opioid use disorder. Despite marketing their products as natural botanicals, they are producing unapproved new pharmaceutical drugs, which is illegal.

In order to protect Americans, they should be conducting rigorous peer reviewed science that is published in a journal and vetted as a part of a robust IND submission that proves the efficacy and safety of 7 and Pseudo in comparison to the prescription drugs they are attempting to mimic. Without this critical research and approval from the FDA for prescribed use of 7 and Pseudo, these products should not be on the market.

The study’s design, results, and implications are expanded upon below:

The original study design sought to give 10, 20, 40 mg of 7-OH or mitragynine psuedoindoxyl twice daily for 7 days for beagles ranging from 8–10.2 kg. However, at the lowest dose of 10 mg, a Serious Adverse Event (SAE) occurred causing the study to be halted).

What does this mean?

• A 10 mg dog for a ~10 kg dog dose ≈ 0.5 mg/kg in humans, or ~32.4 mg in a 60 kg human, potentially enough to cause a similar SAE. [1]
• Based on this data, using a reasonable safety factor of 100 (per FDA guidance), the results would mean the maximum dose they could administer is 0.3 mg for humans. This maximum dose of 0.3 mg is equivalent to about 4% of the suggested serving size, and 2% of a single tablet sold by American Shaman.

After the SAE, the sponsor adjusted its protocol to 1/10 of the original doses (1, 2, 4 mg per day in dogs), which is 1/20 of the daily dose. However, even at doses at 1 mg, 2 mg and 4 mg per day, adverse events (AEs) were still 2.5–2.7x more common than placebo. Specific AEs include GI disturbances, including blood and mucus in feces. All episodes of drooling appeared in dogs only after the daily dose was escalated to 4 mg.

What does this mean?

• 1 mg, 2 mg and 4 mg doses in dogs can be converted to Human Equivalent Dose (HED) of 0.05 mg/kg, 0.1 mg/kg and 0.2 mg/kg.
• For a 60 kg human, the dose that can cause adverse events could be as low as 3.24–12.96 mg.
• The sponsor (CBD American Shaman)’s current human product doses, as well as many 7 and Pseudo products in market already far exceed the Human Equivalent Dose that could cause an adverse event, and many times more than what would be considered a safe dose.

Missing pieces in research design and unfinished reports:

The presented study of 7 and Pseudo in dogs was incomplete, missing key safety endpoints, and inappropriately designed to assess safe use of the test articles. Some of these are described below

• Short duration: Only seven days of exposure per dose, not representative of daily chronic use observed in real-world conditions.
• Within-group dose escalation confounds data: The middle and high doses were only given to dogs acclimated to lower doses of the test article.
• No assessment of opioid-related side effects like respiratory depression.
• No assessment of abuse potential or behavioral changes expected with opioid exposure.
• While allegedly collected, no report of clinical chemistry, hematology, or urinalysis data.
• The study was not peer-reviewed nor published in a reputable scientific journal. In fact, it was still in draft format.

In Summary

The study is incomplete, shows significant public health risk with these products, and it doesn’t justify extrapolating to humans to establish the safety of 7 or Pseudo, especially when:

• The beagles had serious adverse events at very low doses in the original study design and had adverse events in the redesigned studies starting at 1/10 of the dosage of the initial study design’s first dose.
• The set dosing data for humans for products already being sold are based on a leap of faith, not robust safety data.
• Beagle-to-human extrapolation is already a cautious stretch; human sales go far beyond what the model supports. Dosages currently sold in the market have already exceeded the HED that can cause Adverse Events (AEs) and Serious Adverse Events (SAEs) based on the study.
• With reported risk addiction due to 7 being 22 times more potent opioid receptor binding affinity than morphine, many consumers will take more than the 32.4 mg limit that links to serious adverse events and expose themselves at lower doses to high risk of adverse events.

Final Thoughts

What HART is ignoring, irrespective of the science they put forward, is that 7 and Pseudo have been chemically formulated and put into the market with the intent to cure, treat and mitigate disease — namely chronic pain and opioid use disorder. They have intentionally produced a novel drug and are currently marketing it without FDA approval, which is a clear violation of federal law. They should be doing more science as a part of a robust Investigational New Drug (IND) and New Drug Application (NDA) submission that not only proves the efficacy and safety of 7 and Pseudo but also shows that they are better than the drugs they seek to replace (Oxycontin, Percocet, etc.). Until such time that they have done this and gained approval from the FDA for prescribed use of 7 and Pseudo, these products should not be on the market, and should certainly not be available for $6 a pill at your local smoke shop or convenience store.

To learn more about Stop Gas Station Heroin and its mission, navigate to stopgasstationheroin.com.

Sources

[1] Human Equivalent Dose (HED) = Animal Equivalent Dose (AED) x 0.54. This is based on conversion mentioned in study design and also standard dose conversion.

Genus AI, a leader in AI-driven growth solutions for D2C and e-commerce brands, is excited to announce the launch of Sage, a first-of-its-kind AI Growth Agent built to transform how brands scale across digital channels.

Sage is redefining e-commerce growth with an intelligent AI agent that unifies creative generation, product catalog management, digital campaigns, customer insights, and order data. Built for brands of all sizes, Sage can power the entire digital growth engine — enhancing product catalogs, optimizing campaigns, and providing real-time visibility into the customer lifecycle. It’s now available to brands leveraging Shopify and Meta platforms.

In a landscape where digital growth is more vital than ever, Genus AI continues to stand apart by democratizing access to secure enterprise-grade AI technology. The platform currently generates more than 20 million product catalog images and videos each month and is projected to drive over $500 million in revenue from AI-generated campaigns in 2025.

Already trusted by leading brands like Chubbies, Parks Project, Annie Selke, Awe Inspired, Peter Thomas Roth and many others, Genus AI empowers e-commerce teams to unlock scalable growth without compromising brand identity or operational control.

“With Sage, we’re introducing a fundamental shift in how brands harness AI to drive growth,” said Dr. Tadas Jucikas, founder and CEO of Genus AI. “Our mission is to empower businesses with intelligent tools that enhance product catalogs, generate high-performing creatives, and run more efficient campaigns across every digital channel. Sage has the potential to do all of this autonomously, marking the beginning of a new era in e-commerce growth.”

Genus AI is committed to making advanced AI accessible to brands of any size. Later this year Sage will be available via MCP (Model Context Protocol) for AI to AI workflows where brands can automate entire pipelines of deep customer insights, product catalog ad generation and digital campaign optimization in a secure and reliable environment.

As Genus AI continues to expand Sage’s capabilities, the company is paving the way for the next generation of AI-driven agentic solutions that will redefine digital commerce.

To learn how Sage can transform your e-commerce growth, visit: genus.ai/ask-sage

UZCARD, a leader in financial infrastructure development, encompasses all payment components such as issuing, acquiring, card network, payment gateway and aggregator functionalities. It leads the strategic progress of Open Banking roads in Uzbekistan and its ongoing impact on the country’s fintech sector. Leveraging centralized payment processing systems, Uzbekistan is emerging as a Central Asian success story in implementing a secure, scalable, and competitive Open Banking environment.

Open Banking allows consumers to access and share their financial data across platforms via open APIs, enabling third-party developers to build tailored services that aggregate information from multiple institutions. In Uzbekistan, this model is supported by nationwide infrastructure and compliance with personal data protection laws, creating a “bank-agnostic” environment for users.

“With centralized systems like UZCARD, consumers can link their accounts across all local financial institutions in a seamless and secure way. This dramatically reduces customer acquisition cost, boosts competition, and enables a new generation of fintech innovation,” said David Melikidze, CEO of UCMG (UZCARD Management Group).

Unlike in traditional banking systems where financial institutions limit cross-platform access, Uzbekistan’s centralized processing hub provides an integrated foundation for Open Banking. This infrastructure not only benefits consumers but also empowers fintech companies to develop and scale new financial products without requiring large marketing budgets or prolonged acquisition efforts.

Technology Driving Open Banking

Open Banking relies on several core technologies:

• APIs for seamless, secure data exchange;
• Tokenization for protecting sensitive transaction information;
• Centralized processing systems that handle data exchange and payments via interconnected servers, ensuring reliability and speed.

This approach is enabling financial innovation by allowing customers to manage their finances, switch providers easily, and access highly personalized services.

Implications for Emerging Fintech Markets

In markets such as Uzbekistan, the lowered barriers to entry are already fostering a vibrant fintech scene. Startups can integrate with UZCARD to offer services like multi-bank account views (balance aggregation), spending analytics and categorization, transaction initiation and embedded financial products directly within third-party applications. As these capabilities expand, they reduce the relevance of traditional banking interfaces while increasing financial inclusion and diversity.

Looking Ahead: Open Banking Beyond Finance

UZCARD forecasts that Open Banking’s infrastructure and principles will soon extend to adjacent sectors, including:

• Insurance: where consumers can easily compare and switch between policies.
• Healthcare: where medical records can be securely shared among institutions, improving continuity of care.

These developments will further empower consumers by enabling data portability across services and industries.

“Open Banking is not just a technological shift; it’s a new standard for how people interact with their financial and personal data,” added Melikidze.

Inception Research Institute, part of Inception Fertility (Inception), today announced a new partnership with Frame, the collaborative care platform transforming access to reproductive and fertility care, to launch a landmark study focused on one of the most urgent challenges in fertility care: the emotional burden of treatment and its impact on patient retention.

Infertility is one of the most emotionally distressing experiences a person can face — on par with the psychological toll of a cancer diagnosis. Yet despite its intensity, most patients navigate fertility treatment without the emotional support they need. Emotional overwhelm — not cost or access — is the primary reason patients drop out, even with full insurance coverage. With more than half of patients discontinuing treatment, this study highlights a critical, often overlooked solution: addressing emotional needs to help more people stay in care and reach their goal of building a family.

“At Inception, we believe that the patient experience is just as important as the clinical protocol,” said Dr. Alice Domar, chief compassion officer at Inception and director of the Inception Research Institute. “Infertility is one of the most emotionally complex experiences someone can go through. Partnering with Frame — an organization that not only understands that but is deeply committed to studying it — is incredibly exciting. I’ve waited a long time to see this level of innovation in patient experience backed by a commitment to rigorous research.”

The six-month study will include patients across six of Inception’s Prelude Fertility clinics and will randomly assign half of the participants to immediate use of Frame to compare to a control group receiving standard care. Key outcomes will include patient retention, time to treatment, and psychological well-being.

“At Inception, the patient experience is our top priority,” said TJ Farnsworth, founder and CEO of Inception Fertility. “We invest in research and partnerships like this because we believe emotional support is not a nice-to-have — it’s a must-have. This study is about taking action to better serve our patients in every way, not just medically, but as whole people.”

Frame’s virtual care and AI-powered concierge model supports patients and providers across the entire fertility journey — from OB/GYNs and primary care to fertility clinics. The platform offers personalized virtual care and emotional support, holistic education, and end-to-end navigation from the first questions about fertility through treatment.

“We’re honored to partner with Inception and the Principal Investigator, Dr. Domar, to bring deeper insight into what patients really need during one of the hardest times in their lives,” said Jessica Bell van der Wal, co-founder and CEO of Frame.

“As a former infertility patient, I know firsthand the stress doesn’t stop at diagnosis — it continues through every appointment, decision, and outcome. That’s why we built Frame: to ensure patients feel supported emotionally and to rigorously measure what works. This study reflects our commitment to learning from real patient experiences, validating the impact of emotional support, and helping more people stay on the path to building their families.”

About Inception Fertility Research Institute

Established in 2022, the Inception Research Institute advances the field of reproductive medicine by addressing the industry’s most urgent needs—including pharmacological innovation, device development, professional advancement, access to care, and studies exploring how controllable factors such as emotional health and lifestyle habits affect treatment outcomes.

The Institute supports research across The Prelude Network™ — Inception’s national network of top-tier fertility clinics — by centralizing services such as IRB applications, contract review, and patient recruitment. Research conducted through the Institute has been published in leading peer-reviewed journals and presented at global forums such as ASRM and ESHRE, including a landmark 15-year study on egg freezing.

With the largest number of current studies in North America focusing on improving the patient experience, enhancing patient-centered care, researching the relationship between stress and treatment outcome, and investigating the most effective stress-reduction strategies, the Inception Fertility Research Institute continues to be an industry leader.

For more information, visit inceptionfertility.com/inception-research-institute.

To learn about active studies led by the Inception Research Institute, visit fertiltystudies.com.

About Frame

Founded in 2021, Frame is transforming the fertility journey by helping patients get the answers and guidance they need — faster. Designed for OB/GYNs, primary care physicians, and fertility specialists, Frame combines AI-powered tools, care navigation, and patient education to streamline the fertility journey — improving outcomes while easing the burden on clinical teams. Frame partners with over 5,000 OB/GYN, primary care and reproductive endocrinologists or other specialists nationwide. Learn more at www.frameyourfuture.com.

The world of aesthetics is evolving rapidly, and at the heart of this transformation stands a clinic that has redefined beauty standards not just in Turkey, but across the globe: Doku Clinic. Located in Istanbul’s prestigious Nişantaşı district, Doku Clinic has become a beacon of excellence for those seeking safe, innovative, and natural-looking aesthetic treatments. Combining medical expertise, state-of-the-art technology, and personalized care, Doku Clinic is widely regarded as the best aesthetics center in Istanbul.

Aesthetic Excellence Meets Luxury in Istanbul

In recent years, Istanbul has become a global hub for health and beauty tourism. Patients from Europe, the Middle East, Asia, and North America are increasingly choosing the city for its world-class clinics and internationally trained specialists. Within this dynamic landscape, Doku Clinic stands out for its commitment to quality, ethics, and artistry.

What makes Doku Clinic unique is not just the treatments it offers, but the philosophy behind the care: Beauty should enhance confidence, preserve individuality, and promote wellness from the inside out.

Nose Aesthetics Mastery: Functional Beauty with Dr. Serhan Derin

Rhinoplasty is among the most complex and transformative cosmetic surgeries, as it must balance facial aesthetics with breathing functionality. Dr. Serhan Derin is a leading name in this field, recognized for his ability to tailor every nose surgery to the patient’s facial structure and medical needs.

Whether it's primary rhinoplasty, revision rhinoplasty, or ethnic rhinoplasty, Dr. Derin designs subtle, natural-looking noses that fit the patient’s overall features. At the same time, he ensures any breathing difficulties are resolved, dramatically improving quality of life.

His commitment to personalized care and natural aesthetics aligns perfectly with the current trend: avoiding “overdone” results and enhancing one’s own beauty.

Global Trust in Breast Aesthetics: Why Amanda Du Pont, Alessia Spagnulo, and Priscila Da Silva Chose Doku Clinic

Doku Clinic’s rising global profile is partly due to the international influencers who openly share their aesthetic journeys on social media. These women, with millions of followers, chose Doku Clinic for one life-changing procedure: breast augmentation.

Amanda Du Pont, South African actress and content creator, came to Istanbul specifically for her breast augmentation at Doku Clinic. She praised the clinic’s warm hospitality, high-level professionalism, and the natural results achieved by Dr. Engin Öcal. Amanda shared her positive experience openly, encouraging her followers to choose Doku Clinic with confidence.

Alessia Spagnulo, a popular fashion influencer from Italy, had been considering breast augmentation for a long time before choosing Doku Clinic. After her surgery, she shared how the procedure significantly improved both her physical appearance and confidence. She specifically appreciated the tailored approach and how well the result complemented her body.

Priscila Da Silva, a Brazilian fitness and lifestyle influencer, underwent breast augmentation to achieve a more proportionate and balanced figure. In her posts, she emphasized how smooth and reassuring the whole experience was—from pre-op consultation to recovery. She described Doku Clinic as a place that “makes you feel reborn.”

Meet the Minds Behind Doku Clinic

Founded by a team of experienced plastic surgeons, dermatologists, and aesthetic experts, Doku Clinic is led by visionaries who are passionate about harmonizing science and beauty. Among them, Dr. Engin Öcal—an internationally renowned plastic surgeon—plays a key role in the clinic’s rise to international fame. With advanced training from Europe and extensive experience in facial and body aesthetics, Dr. Öcal and his team have earned the trust of thousands of patients worldwide.

Comprehensive Services: From Skin to Sculpture

Doku Clinic offers a full spectrum of aesthetic services, each designed with precision and performed using the most advanced technology available. The clinic specializes in:

Facial aesthetic surgeries:

• Rhinoplasty (nose reshaping)
• Facelift and neck lift
• Blepharoplasty (eyelid surgery)
• Chin and jaw contouring

Body contouring procedures:

• Liposuction and HD liposculpture
• Tummy tuck (abdominoplasty)
• Brazilian butt lift (BBL)
• Mommy makeover surgeries

Breast aesthetic surgeries:

• Breast augmentation
• Breast reduction
• Breast lift

Non-surgical treatments:

• Botox and dermal fillers
• Mesotherapy and PRP
• Medical skin care and peelings
• Laser treatments and hair removal

Each treatment is tailored to the patient’s unique anatomy, lifestyle, and beauty goals. Doku Clinic believes there is no “one-size-fits-all” in aesthetics—personalization is key.

Advanced Technology Meets Artistry

What distinguishes Doku Clinic from other centers is its investment in technology. From 3D facial simulation tools to robotic-assisted procedures, the clinic uses cutting-edge devices that improve precision, reduce recovery times, and ensure natural results.

For instance, their Vectra 3D Imaging System allows patients to visualize their post-surgery outcomes even before the procedure, giving them confidence and clarity in their decisions. Additionally, minimally invasive methods such as ultrasound-assisted liposuction and CO2 laser resurfacing are regularly performed to enhance outcomes with minimal downtime.

A Personalized Patient Journey

Doku Clinic doesn’t just treat patients—it guides them on a journey. From the moment a patient makes an inquiry to the final follow-up appointment, the experience is designed to be seamless, safe, and supportive. The multilingual team assists international patients with:

• Free online consultations
• Treatment planning and scheduling
• Hotel and flight arrangements
• Airport transfers and city tours
• Post-operative care and follow-up support

This 360-degree service model has made Doku Clinic the clinic of choice for thousands of patients from countries like the UK, Germany, France, the Netherlands, UAE, Qatar, and Canada.

Why Doku Clinic Is Recognized as the Best in Istanbul

International accreditation and safety standards

Doku Clinic operates under strict international guidelines for hygiene, patient care, and medical ethics. All surgical procedures are performed in accredited hospitals equipped with ICU-level safety standards.

Multidisciplinary medical team

From plastic surgeons to dermatologists, anesthesiologists, nurses, and aesthetic technicians, the clinic brings together top-tier talent who work collaboratively to deliver optimal results.

Natural results and high satisfaction

The clinic’s signature aesthetic is natural elegance—enhancing what’s already there without creating an artificial appearance. Patients consistently report high satisfaction rates and long-term confidence boosts.

Transparent pricing with no hidden costs

Unlike many clinics, Doku Clinic provides clear, all-inclusive treatment packages, covering medical expenses, accommodation, transfers, and aftercare. There are no hidden surprises—only transparent communication and trust.

Success Stories from Around the World

With over 15,000 satisfied patients to date, Doku Clinic’s reputation extends far beyond Istanbul. One patient from London who underwent a combined rhinoplasty and liposuction shared:

“I had researched clinics in Spain, Hungary, and Turkey. Doku Clinic was the only one that felt professional and caring from the start. Dr. Öcal listened, understood, and delivered exactly what I hoped for—natural, balanced beauty.”

Another testimonial from a patient in Dubai highlighted the holistic care model:

“It wasn’t just about surgery. They made sure I was emotionally ready, informed, and comfortable. It felt like a five-star wellness retreat with medical precision.”

Beauty in the Heart of Istanbul

Part of what makes the Doku Clinic experience special is its location. Nestled in the elegant neighborhood of Nişantaşı, the clinic is surrounded by boutique hotels, designer shops, art galleries, and gourmet restaurants. Patients often extend their stay to recover in luxury while exploring one of the most culturally rich cities in the world.

Doku Clinic also collaborates with local wellness centers, offering recovery spa packages, nutritional guidance, and private healing retreats, ensuring that patients not only look better but feel healthier and more rejuvenated.

Post-Procedure Support and Follow-Up

Doku Clinic understands that true care continues after the procedure. That's why the clinic provides a robust post-operative follow-up system including:

• In-clinic follow-ups during the stay in Istanbul
• Remote video check-ins after return home
• 24/7 WhatsApp support for healing guidance
• Access to personal patient coordinators for ongoing communication

A Vision for the Future: Ethical and Empowered Beauty

Doku Clinic’s mission extends beyond aesthetics. The founders advocate for ethical beauty, rejecting over-commercialization and promoting body positivity, confidence, and individual empowerment. As global demand grows, the clinic continues to expand its services with new departments in regenerative medicine, stem cell treatments, and non-invasive anti-aging therapies.

“We believe that true beauty is a balance between science, art, and soul,” says Dr. Öcal. “We’re not here to change faces—we’re here to help people love themselves more.”

Ready to start your aesthetic journey? Meet Doku Clinic—where beauty and confidence meet.

In June 2024, Devoteam announced the acquisition of Ubertas Consulting, a leading UK-based AWS consultancy. The move strengthened Devoteam’s presence across the United Kingdom and Ireland, expanding its reach to deliver exceptional services in cloud, data, cybersecurity and artificial intelligence to a client base across industries and public institutions.

The strategic and targeted acquisition created Devoteam UK, an integrated organisation that is positioned to scale and meet the rising demand for AWS solutions across the EMEA region, empowering businesses to achieve their digital transformation goals. It reflects Devoteam’s growth trajectory and commitment to deliver unparalleled Cloud solutions and provide enhanced customer value through expanded knowledge and deep industry expertise.

The Ubertas Consulting acquisition has been the latest in a number of high profile acquisitions from 2017 to 2024 as Devoteam expands its services and geographic footprint. Globally, the company has also developed key strategic partnerships with not only AWS, but Google Cloud, Microsoft and ServiceNow alongside a broader ecosystem of partners, as it continues to offer tailored and specialised services to each.

The strategic partnership announcement with ServiceNow demonstrated even more growth plans across the EMEA region and followed the acquisition of Eraneos in the Netherlands last year. Stanislas de Bentzmann, founder and CEO of Devoteam, recently attended the AWS Summit in London with an objective to reinforce Devoteam’s knowledge and understanding of the latest innovations in the cloud computing space.

Speaking at the recent launch of Devoteam UK, Bentzmann discussed the company’s strategic plans, partnerships and hopes for further growth across Europe despite wavering support from the United States:

“Some things we cannot disclose yet; however, we can share that we are in the ongoing process of developing our footprint in the EMEA region to support our customers there in the best way possible, which involves concentrating talent density.

We have plans to reinforce our talent pool with a strong management team, similar to what we’ve achieved here in the UK by bringing Ubertas Consulting into Devoteam. We seek strong expertise with in-depth AWS knowledge to solidify our presence with the highest level of expertise in the market, as we have achieved by merging AWS and ServiceNow with Devoteam, consistently expanding to service our clients optimally.

We are organised to support our strategic partnerships with four of the well known tech providers (Microsoft, ServiceNow, AWS and Google). We see NVIDIA as our fifth partner shortly. We then focus on these five strategic partners, all of whom are experts with a strong and reputable presence in their respective markets. They all possess the necessary know-how and are well-positioned for expansion.

More importantly, each partner will leave with a comprehensive understanding of each other's expertise and capabilities. We will adapt, bond, and understand our strengths to address the market better than ever before.

The goal is that the five teams come together as one united force with greater capabilities. A melting pot of diverse expertise and know-how from different regions, where each of the five was already a dominant force.

We have combined Google, AWS, and ServiceNow in the UK. We are now developing AWS and ServiceNow as a combined force that we can heavily promote and achieve great success with. DataBricks is another layer that is very strong. They possess exceptional data management skills, combined with cloud capabilities, to deliver the most optimal data to AI tools.”

Much of the talk at AWS Summit centered around how Microsoft vowed to protect its European operations, even if U.S. President Donald Trump tries to block the continent from using its cloud services.

A  bullish Bentzmann said that the situation brought on by the Trump administration demonstrates that UK and European companies must acknowledge more complexities in the immediate future:

“The U.S. cloud is the leading cloud in Europe. Due to the differences in the Chinese cloud, Europeans have been more trusting of the U.S. cloud so far. Even if we were a little surprised and uncomfortable with the Patriot Act signed by President Trump during his first term, we trust the U.S. tech and the U.S. Cloud. And that's what you can see, that the Chinese cloud is so small. There is now a growing awareness that we should be more cautious, as we can see that it's a risk we may not have fully appreciated over the last few years.

We see two kinds of sovereign clouds. The one like Thales with a product called S3NS in this larger organization. They are building a cloud solution on Google technology, but run by Thales data centers. So, it's Google technology run by a European organisation, and it's secured in that way so that nobody can access customers’ data. So that's one answer. There is another one, run by Microsoft, called Cloud for Sovereignty, which gives access keys to the data only to the customers. 

However, this might not be entirely comfortable for customers, as technology provides robust security. However, they still doubt what will happen in the event of a conflict between Microsoft and the customer.

So that's a second option. The third one is that you can see complete local solutions such as OVHcloud and Numspot emerging on the market. Are they sufficiently innovative? The answer is so far no, they are not a solution. We have some in France and in Germany, but they don’t invest enough in technology, and innovation is limited due to limited means.

This adds complexity for the customers. For a company like Devoteam, complexity means customers are looking for advisors like ourselves. So, the fact that we are talking with our large customers about not moving to the U.S. cloud anymore, but instead splitting or dividing up what you need to keep, and how you can build your own private cloud, or go to a sovereign cloud, which means they will need us because all this dimension implies additional complexity, and that's good for business.

And the question is everywhere on the table, in all geographies, in all countries. In European countries. And not only in Europe, but also in the Middle East.”

Despite this, Bentzmann does see positives emerging with support from established and new companies. 

“You know that when something becomes more expensive, more space is created for newcomers. I believe it's a plus, and I also don’t think Microsoft, Google, or Amazon want to lose their European customers. No, that's not a game they want to play. On the contrary, they are in the game to increase their market share.”

Adaptaphoria by Global Can Beverage (GCB), the fast-rising brand redefining the THC beverage market, is rolling into summer with unstoppable momentum. The next stop on its high-energy road tour is the Hemp Beverage Expo, taking place from July 9 to 11 at the Omni Atlanta Hotel. This premier executive-level gathering, dedicated exclusively to hemp-infused beverages, is the perfect stage for showcasing Adaptaphoria’s bold and functional lineup.

Catch Adaptaphoria at Booth 613

Following a powerful showing at 101 Distributors’ record-breaking Customer Tradeshow, Adaptaphoria is poised to keep the buzz going strong. At that event, 101 Distributors GA (Stone Mountain, GA) secured a major order that will rapidly expand Adaptaphoria distribution into Georgia, Pennsylvania, Tennessee, South Carolina, North Carolina, Kentucky, Alabama, Florida — a clear testament to the brand’s industry-leading taste, quality, and market demand.

“Everyone was raving about the taste, low calories, and low sugar content. Adaptaphoria is right on target with shifting consumer trends, and we are here to support our customers’ needs,” said Mr. Patel, of 101 Distributors GA.

Expanding Reach Across the Southeast

This partnership brings Adaptaphoria’s signature experience to more shelves and more consumers throughout the Southeast and beyond, reinforcing the brand’s growing influence and traction with both retailers and fans.

Created by a Proven Visionary

Founded by serial entrepreneur Cameron Forni, Adaptaphoria is already outpacing the legendary success of his previous cannabis unicorn, Select, which was acquired by Curaleaf ($CURLF) to create the world’s largest cannabis brand. The all-stock deal, which peaked just north of a billion CAD during the close.

"Adaptaphoria is disruptive; we are bringing new customers into the category and giving non-drinkers a better way to socialize and rejoin the fun!" said Forni.

Forni spent years researching and analyzing the market and formulation with his team to chart a new course in the booming THC beverage market, creating a product that’s sophisticated, health-conscious, and ready for today’s mindful social drinker.

"When I realized we had achieved what we did with Select, I was filled with gratitude. That same feeling returns now with excitement for this partnership. After experiencing the joy, volume, and sheer demand at 101’s Vendor Event, we’re energized for what’s next,” added Forni.

The Social Spark for a New Generation

At the heart of Adaptaphoria is a mission to inspire real connection, spark entrepreneurship, and help end loneliness, one can at a time. Its USDA Farm Bill-compliant, delta-9 THC-infused functional seltzer offers a clean, clear-headed lift without alcohol’s downsides, perfect for anyone cutting back on booze and sugar but still craving a true happy hour vibe.

Adaptaphoria isn’t just a drink — it’s a movement. Each stop on the tour expands the brand’s footprint, from shelf space to community space.

Monthly Gatherings to Grow the Movement

To bring its vision to life, Adaptaphoria will be hosting monthly gatherings in each launch city — curated experiences designed to unite top entrepreneurs, creators, and athletes for evenings of connection, collaboration, and inspiration. Expect stories, laughter, and momentum-building moments.

We begin this journey in Miami, Florida, with the founders of none other than Maison Mura, a name synonymous with refinement, elegance, and exceptional taste. With a reputation for stocking only the most luxurious brands and impeccable products, Maison Mura embodies the very essence of excellence. Known as the “house of good moments” and boasting 290+ five-star Google reviews, it is an extraordinary honor to host our inaugural launch party in such a distinguished space.

We’ll be announcing the event date soon. Don’t miss it, follow @maisonmura.wine for exclusive details.

Visit us at Booth 613 at the Hemp Beverage Expo, July 9–11, at the Omni Atlanta Hotel.

Expand your network. Expand your mind. Expand the movement. #TimeToAdapt

LIFTEX, a national leader in structural roof lifting, has relocated its headquarters to a newly acquired office space designed to support the company’s continued growth, improve team collaboration, and create a more professional environment for client meetings.

The move to 431 Route 10, Suite 2 in Randolph, New Jersey comes as the LIFTEX team outgrew the layout and limitations of their previous office. “Our old space just wasn’t set up for the way we work today,” said Matt De Vito, project manager at LIFTEX. “Desks were placed wherever they could fit, and our conference room doubled as the kitchen and print area … not ideal for hosting clients or working efficiently as a team.”

The new office resolves those challenges with more dedicated offices and an improved floor plan, enabling everyone to work more comfortably. A fully equipped, purpose-built conference room also allows the team to meet with clients in a more professional setting.

The new building is about double the size of the previous, with LIFTEX using the second level and the main level leased by other tenants. About one third of the main level is under flexible, short-term lease, which gives LIFTEX the option to expand internally as the company grows. Parking, previously a pain point for visitors and staff alike, is no longer an issue at the new location.

“This move is about setting ourselves up for the future,” said John Bernauer, LIFTEX's president. “We have a better day-to-day environment for our team, and we’re able to present ourselves in a way that matches the quality of the work we do.”

The new office is located just 10 minutes from LIFTEX’s previous headquarters and remains 5 minutes from the company’s primary steel fabrication facility.

From AI-powered design tools and tax services for ex-pats to next-gen hosting and customer call automation, StartupMafia highlights these ten emerging companies that are quietly defining what practical tech looks like in 2025:

MightyCall: MightyCall offers a cloud-based call center platform explicitly designed for small and mid-sized teams that require flexibility without IT overhead. The system consolidates phone, text, and voicemail in one dashboard, while its AI features, including instant call summaries, provide teams with context without requiring them to sift through recordings. Predictive dialers and live analytics help reduce handling time by an estimated two hours weekly. With always-on infrastructure and human-first control over outbound dialing, MightyCall makes enterprise-grade communications practical and sustainable for growing businesses.

Zomro: Zomro is a global VPS hosting provider with 11 years in the market and over 220,000 users. It offers server deployment in under a minute, a 30-day free trial, and 24/7 multilingual support. Data centers in the Netherlands, Poland, and the U.S. provide regional speed and security, while support for major CMS platforms and crypto payments adds convenience. A built-in no-code website builder and flexible affiliate program round out its offerings for startups seeking scalable infrastructure with minimal friction.

Skyvia: Skyvia is a no-code data integration platform that simplifies ETL, ELT, Reverse ETL, and live data sync across 200+ systems. Its drag-and-drop interface enables non-technical users to automate data pipelines, sync SaaS apps, and run SQL queries without development support. From marketing automation to SaaS backups and warehouse transfers, Skyvia empowers business teams to unify data operations and eliminate silos. Standard integrations include Salesforce, Google BigQuery, Redshift, and more, supporting analytics and operational agility across departments.

Paintit: Paintit is a browser-based, conversational design platform that helps users easily redecorate their interiors. Using a simple chat interface, users upload photos, describe their ideal space, and receive styled renderings complete with product links from retailers like IKEA and Amazon. With no downloads or prior design experience required, Paintit.ai caters to renters, homeowners, and digital creators seeking quick and affordable visual upgrades. It streamlines interior design through intuitive automation and retail integration.

AltTextify: AltTextify is an AI-driven alt text generator that produces descriptive, SEO-optimized, and ADA-compliant image text at scale. Supporting over 140 languages and platforms, including Shopify, WooCommerce, and BigCommerce, the tool automates accessibility and enhances image search indexing. Bulk processing features and browser extensions enhance usability for content-heavy teams managing ecommerce, publishing, or large CMS systems. As regulations tighten and inclusivity becomes non-negotiable, AltTextify offers a reliable solution for visual accessibility.

FBS: FBS is a global trading platform built for speed and strategic insight. It supports over 550 trading instruments, including forex, commodities, and indices, with execution speeds as fast as 0.01 seconds. The platform combines customizable leverage (up to 1:3000) with real-time benchmarking, analytics dashboards, and campaign tools for finance marketers. Its user-friendly UI, instant withdrawals, and market segmentation features serve both individual traders and financial services teams operating in time-sensitive environments.

EVA: EVA is Ukraine’s leading digital platform for beauty, health, and household goods, offering over 200,000 products and serving as the online arm of a 1,100-store chain. During periods of supply chain disruption, EVA ensures nationwide access to essential items through synced inventory, national delivery, and affordable pricing. Its combination of local footprint and ecommerce resilience makes it a critical service layer for consumers in uncertain economic conditions.

Saliutas: Based in the Baltics, Saliutas supplies high-purity pyrotechnic chemicals like silver nitrate and copper chloride to global fireworks manufacturers. It contributes data to EU regulatory reports and supports industry efforts to achieve more precise and sustainable outcomes. As the fireworks sector evolves toward safety and environmental responsibility, niche suppliers like Saliutas provide not only ingredients but also the compliance infrastructure needed for innovation.

Sellme: Sellme is a leading Estonian e-commerce marketplace with over one million products across more than 1,000 categories. Founded in 2020, the platform bridges EU sellers and Baltic consumers through local language support, regional logistics, and apps for both iOS and Android. With a deep catalog and frictionless checkout, Sellme offers a localized alternative to global ecommerce giants, enabling small sellers to scale in a digitally maturing region.

PsychicOz: PsychicOz, an online psychic readings provider, offers live guidance from verified advisors via phone, chat, and video. Topics include relationships, career decisions, and personal development, delivered through a curated network of experienced psychics. The platform prioritizes human interaction over automation, backed by transparent pricing, instant availability, and authentic user reviews. In an era when emotional support is often algorithm-driven, PsychicOz offers real-time, human-centered insights for users navigating life’s uncertainties.

Together, these ten platforms illustrate a clear trend for 2025: solutions that emphasize utility over hype. Whether it’s reducing call center overhead, enabling real-time tax compliance, or speeding up cross-platform data sync, each company delivers measurable improvements in how people work, shop, and connect. Quietly but effectively, they are redefining productivity, accessibility, and digital service delivery for global professionals and teams of all sizes.

Headway Inc, a full-scale consumer tech platform revolutionising lifelong learning, raised investment from Bullhound Capital, a leading global technology investment firm. This strategic investment enables Headway Inc to accelerate product development, expand internationally, and strengthen its knowledge-driven ecosystem.

Since its founding in 2019, Headway Inc has grown into one of the most recognised names in consumer EdTech, reaching 150 million downloads across 170+ countries. With 100% year-over-year growth, the company has achieved profitability while scaling its global impact. Its flagship apps — Headway, Impulse, and Nibble — consistently rank among the top on global app stores, reflecting strong demand for habit-forming learning solutions. The platform delivers personalised learning experiences, including book summaries, brain-training games, and social skills development, empowering users to learn and grow seamlessly.

"Headway Inc is a prime example of how personalized and gamified experiences are reshaping consumer engagement at scale. Their vision is closely aligned with Bullhound Capital’s mission to disrupt outdated systems and champion the use of AI tools to solve real-world problems. We are delighted to invest in this round, providing both financial backing and strategic guidance to help Headway Inc expand its presence in new markets," said Per Roman, Founder and Managing Partner at Bullhound Capital.

With new investment, Headway Inc is launching a European hub in Madrid to grow its brand and speed up product innovation and regional expansion.

This milestone also aligns with another major achievement: being named a Top 4 company on TIME’s 2025 World’s Top EdTech Companies list, highlighting its global leadership in educational technology.

"At Headway Inc, we are on a mission to help people grow by making lifelong learning not only accessible but truly engaging and impactful. This investment allows us to scale our technology, expand into new markets, and continue innovating to meet the evolving needs of modern learners. We are excited to welcome Per Roman, founder and managing partner of Bullhound Capital, to our board, strengthening our governance and strategic direction," said Anton Pavlovsky, Founder and CEO of Headway Inc.

In response to the demands of the ever-evolving world, the partnership empowers Headway Inc to further unroll a new era of lifelong learning, tailored to digital-first generations who are too often written off as distracted. Rather than competing for attention, Headway Inc aims to complement the rhythm of modern life, supporting ongoing growth through personalised and focused learning sessions.

"This partnership represents a significant milestone in Headway Inc’s journey, bringing strategic validation to our vision of transforming the lifelong learning market. The investment is a natural evolution of our long-standing relationship with Bullhound Capital, built on their deep expertise in consumer subscription software," said Oleksandr Yaroshenko, Chief of Staff at Headway Inc.

Bullhound Capital made this investment through its Fund VI, which also supports late-stage ventures such as Q-CTRL, LeoLabs, EcoVadis, CoverManager, Mentimeter, Sanity, and Sesame HR. This is Series A funding for Headway Inc. It also represents the largest investment through Bullhound Capital's Fund VI to date.

About Headway Inc

Headway Inc is a global consumer tech company that revolutionizes lifelong learning. The company develops digital educational products that make knowledge more accessible, personalized, and impactful for over 150 million users worldwide. Previously known as Headway, the company officially evolved into Headway Inc in April 2025. Headway Inc is the creator of Headway, the world’s most downloaded book summary app, Impulse, a top-ranked brain training app, Nibble, an all-around knowledge app, and other innovative learning solutions. Recognized by TIME, Global Silicon Valley, and HolonIQ, Headway Inc continues to transform the way people learn.

For more information, visit www.headway.inc.

About Bullhound Capital

Bullhound Capital is the investment management arm of GP Bullhound, building with founders creating category-leading technology companies. With over €1 billion under management and 25 years of performance, it has invested in global leaders like Spotify, Slack, Klarna, Unity, Connex.ai, and EcoVadis. Operating from 13 offices worldwide, its platform delivers hands-on, founder-focused support across strategy, growth, and execution. From quantum to entertainment, Bullhound Capital backs global leaders applying Artificial Intelligence to solve real-world problems.

For more information, visit bullhoundcapital.com.

Kratom Consumer Advisory Council (KCAC) today released a position statement about Holistic Alternative Recovery Trust (HART)'s new “animal safety” study.

HART's Claim

On July 7, 2025, the HART published a press release with a link to a new study they believe shows that 7-hydroxymitragynine (7-OH) products are safe. As they state clearly in their press release:

“Adding to the body of evidence, a new 2025 study by East Tennessee Clinical Research gave dogs extremely high doses of 7-OH (up to 10 times the typical human dose). The results:

• No cardiac, neurological, or behavioral harm
• The only observed effect was mild, temporary drooling, even at the highest dose
• All animals fully recovered with no lasting impact”

C. Michael White, Pharm.D., FCP, FCCP, FASHP, and KCAC chair, reviewed this 2025 pilot study in beagles and believes that three of these claims are untrue and that the study, in fact, shows serious health concerns for 7-OH and pseudo products.

No Neurological Harm was Found?

According to this paper, the original dose protocol was 10 mg twice daily for 7 days, 20 mg twice daily for 7 days, and then 40 mg twice daily for 7 days. However, when they gave the first beagle the very first 10 mg dose, the beagle had severe neurological issues (severe central nervous system excitation followed by severe central nervous system depression). The adverse event was severe enough that they scrapped the entire original dosing protocol and rewrote it to give the beagles only 1/20th the total daily dose (1 mg once daily for 7 days, 2 mg once daily for 7 days, and 4 mg once daily for 7 days).

The following is an excerpt from the report:

“15.7.1 Adverse events at a higher dose

The study reported herein was modified from an original protocol in which escalating treatments of 10, 20 and 40 mg of MGN were to be administered twice daily. After the first dose of 10 mg, one dog (XYL-4) exhibited marked central nervous system excitation, followed by marked CNS depression. This was classified as a Serious Adverse Event and its relation to treatment with IVP was deemed “probable”, so the trial was discontinued after only one dose and the protocol was amended to reflect the study design reported herein. The amended study design features lower doses and only once daily administration.” 

HART’s own scientists believed that 10 mg twice daily should have been safe, which is why it was the smallest dose that they intended to give the beagles. It was, in fact, not safe and suggests that HART scientists cannot actually predict the safety of their products in humans given the available data. Since HART’s own scientists are touting this study as major proof of safety but did not mention this serious adverse event in their press release, it shows that they do not actually know what is in their own report and its serious potential health implications, or they are hiding this information from the public. Either reason is unconscionable and alarming for public health.

Please see Table 1 (attached) for the dosing schema they intended to give the beagles as evidenced by the excerpt from the report.

The Dose of 7-OH Given Was 10x the Human Dose?

According to the FDA, a dose of 1 mg in a beagle is the same as a 3 mg dose in a 60 kg human. Please see Table 3 (attached) which is the dose conversion table from their guidance.

Use the online calculator to perform the calculation yourself, in accordance with FDA guidance:

1. Select dog as ‘from species’
2. Select human as ‘to species’
3. Input the dose administered in mg/kg which is 0.1 mg (1 mg divided by the 10 kg weight for a beagle
4. Enter 60 as the target body weight (a 60 kg human)
5. When you calculate it, the result is 3 mg

Even the 10 mg dose they intended to give (but could not because of the severe neurological issue) would have only been the equivalent of a 32 mg dose in humans.

There are products with 30 mg of 7-OH per serving in them now, and it is common to find 10–15 mg products. As such, the 1 mg, 2 mg, and 4 mg doses that they used are actually 3–5 times lower or similar to what is typically used in humans and clearly not 10x the human dose.

Please see the dosing screenshot (attached) for the dosing regimen they used in the beagle pilot study. “SID” is a veterinary term for once daily.

The KCAC cautions consumers that rodent studies already found rapid tolerance develops with 7-OH, so giving 1 mg for 7 days and then 2 mg for 7 days, and then 4 mg for 7 days does not mean that the adverse effects found at the 4 mg dose would be the same if 4 mg were given up front to the beagles without getting them accustomed to the effects.

The Only Observed Effect Was Drooling at the Highest Doses?

This is a gross oversimplification of their data. The investigators said this about adverse events, as evidenced by this report excerpt:

“The frequency of Adverse Events was calculated as the total number recorded per group divided by the number of dogs in the group. The comparative frequency of AEs for the various groups were:

• Group 1 (7-hydroxymitragynine) 20/6=3.333
• Group 2 (Pseudoindoxyl mitragynine) 19/6=3.167
• Group 3 (placebo) 5/4=1.25

Thus, treatment with 7-OH MGN or Pseudoindoxl MGN was 2.66 and 2.53 times more likely to cause Adverse Events, respectively, compared to placebo-treated controls.

Five observations of drooling in two different dogs were considered probably associated with treatment. It is significant to note that all episodes of drooling appeared in dogs only after the daily dose was escalated to 4 mg.”

They found 2.7 times more oral-gastrointestinal adverse events when using 7-OH than when they used a placebo. The adverse events that they found can be seen in the “Adverse Events Table” (attached) that was pulled from a data table in their report (Group 1 is 7-OH, Group 2 is mitragynine pseudoindoxyl, and Group 3 is a placebo).

While the investigators were able to say that the drooling with 7-OH was “probably” related to the drug, there were other adverse events that occurred, such as unformed feces, mucus in the feces, blood in the feces, and vomiting, that were all “possibly” related to 7-OH. The determination was never that it was “doubtfully” related or “unrelated.” By their own terminology, it is possible that 7-OH could be responsible for all those adverse events. One thing that strengthens the association is the difference in the number of animals with oral or gastrointestinal issues. Five of the 6 dogs (83.3%) receiving 7-OH had any oral-gastrointestinal adverse events versus only 1 of 4 placebo dogs (25%), a 3.3 fold increase.

Finally, many people may not know that new-onset drooling in dogs can be an early marker of sedation or drug toxicity. When unexplained excessive drooling occurs and there is a new drug or substance ingestion, it is advisable to contact a veterinarian. Remember, the investigators cut back the daily dose to 1/20th of what was originally intended (40 mg twice daily was the highest dose they wanted to give, but it would have been too toxic, and 4 mg once daily was the highest dose they did give). This suggests that at 4 mg, even after 14 days of acclimation and tolerance development, there may still be neurological effects as evidenced by the onset of drooling.

Conclusions

HART put out a press release that they know, or should know, contains three verifiable falsehoods (out of four total statements). This suggests that they are attempting to manipulate available data to create a narrative unaligned with reality. The truth is, there is insufficient evidence to suggest that 7-OH provides any benefits, and there are rodent studies that suggest it causes addiction, rapid tolerance, withdrawal, and respiratory depression (especially at higher doses). This beagle trial did not assess for addiction, tolerance, withdrawal, or respiratory depression and doesn’t suggest safety for any of those outcomes of interest. This beagle study took blood and urine samples to assess for safety, but those results are not presented in the report that was released. This beagle study suggests that when doses on the upper end of what is recommended to consumers in 7-OH products are used, there could be severe neurological issues. Consumers have no limitations on what quantities they can purchase, so a consumer can readily purchase and consume a dose that is 10 times the suggested serving, and there is no healthcare professional to prevent it or counsel them against it. This is very risky for public health.

Tribuna.com, the global digital sports media company, has launched its new flagship app, Football Xtra — an all-in-one destination for football fans worldwide. The app blends real-time match stats, breaking news, editorial coverage, player data (including salaries and transfer values), and interactive fan-driven features. The app is designed to make following football faster and more personalized than ever.

The team behind this launch brings over 15 years of experience in sports media, having run major websites and club apps with millions of visitors.

"We built this app to give every football fan instant and intuitive access — whether you're on the sofa or just need a quick, flash update while on the move," said Dmitriy Navosha, co-founder of Tribuna.com. "Our goal was to combine the best of live data, expert insights, and real football conversations, all in one place."

Football Xtra delivers match results, tournament tables, and live statistics from over 600 competitions across more than 160 countries. From the world's top leagues to local divisions, users get access to advanced in-game analytics, including touches, tackles, and more, all with full historical archives.

As a sports media tech company, Tribuna.com's standout contribution is the fan-powered ecosystem at the heart of Football Xtra. The platform features match chats, user blogs, polls, and comment rankings — built for fans who want to go beyond scrolling. Football Xtra is where users can create, connect, and build a personal media presence, right inside the app.

"We go further than focusing solely on the scoreline, bringing you the full story, including reactions from the community that lives and breathes the game. The app is filled with dynamic stats that update in real time," added Maks Berazinski, Tribuna's co-founder.

Football Xtra by Tribuna.com also offers unique financial data insights, including player salaries, transfer stories, and fan-friendly metrics like cost per goal or minute played. Whether users are tracking player's touches, shots, or revisiting playing days, the data is all there, live, and in-depth.

Serving audiences across the world's biggest markets in eight languages, Tribuna.com's launch of Football Xtra marks its biggest goal yet toward becoming the go-to second screen for modern football fans.

This year marks an incredible milestone for JeraSoft as we proudly celebrate 20 years of delivering cutting-edge telecommunication billing solutions and building lasting partnerships across the globe.

What began in 2005 as a vision to simplify telecom billing has grown into a trusted, international company serving clients in over 35 countries and helping businesses across telecom and cloud industries thrive. From our very first deployment to our latest version of the JeraSoft Billing, we’ve remained committed to delivering flexible, reliable and innovative solutions that empower our customers to succeed.

JeraSoft has always consistently prioritized relationships as much as results. We have always tried to treat customers as our family and will continue to do so with care, trust and long-term commitment at the core of every interaction.

"We’re not just celebrating years. We’re celebrating the people, the challenges we’ve overcome together, and the trust our clients place in us every day," says Andrii Zinchenko, co-founder of JeraSoft. "This anniversary is a heartfelt thank you to our clients, partners and our incredible team who made this journey possible."

Over the past two decades JeraSoft has:

• Supported hundreds of telecom providers, ISPs and service operators in streamlining and automating their VoIP billing processes
• Delivered numerous successful integrations with major telecom switches, ensuring seamless compatibility and deployment
• Earned a reputation for outstanding customer support: fast, responsive, and genuinely invested in client success
• Maintained a strong presence at leading international telecom exhibitions, staying connected with the industry and clients worldwide
• Gained the trust of major enterprise-level partners through complex integrations, including tax automation tools used by market leaders in the U.S.

What began in 2005 as a vision to simplify telecom billing has grown into a trusted, international company serving clients in over 35 countries and helping businesses across telecom and cloud industries thrive. Today, JeraSoft stands as a leader in the industry, recognized as the top telecom billing software provider for its unmatched flexibility, performance, and innovation. From our very first deployment to the latest version of JeraSoft Billing, we’ve remained committed to delivering solutions that not only meet the complex needs of our customers but also empower them to scale, adapt, and succeed in a rapidly evolving digital landscape.

As we look to the future, we’re more energized than ever to continue growing, innovating, and exceeding expectations. Our 20th anniversary is not the finish line; it’s just another exciting chapter.

Xecta has expanded its partnership with global energy company Santos to scale the deployment of the Integrated Production System Model (IPSM) across the company’s assets in Eastern Australia and Papua New Guinea. The five-year agreement follows a successful rollout in the Cooper Basin and will now extend to Santos’ Coal Seam Gas, and PNG operations.

Developed by Xecta, IPSM is the first solution of its kind to provide real-time, system-wide production optimization insights across the full production chain—from reservoir through wells and pipeline networks to the facility inlet. By continuously analyzing billions of telemetry data points and automating engineering workflows, the platform delivers insights that are impossible to replicate manually or with traditional tools.

The initial deployment in the Cooper Basin—spanning more than 1,000 wells and 10 satellite facilities—has already driven a measurable uplift in production. The scale and success of this rollout earned global recognition: Santos was honored for upstream innovation at the 2024 Platts Global Energy Awards by S&P Global Commodity Insights, and Xecta was named a finalist for Commercial Technology of the Year.

In one of the harshest and most operationally complex environments in Australia, IPSM has supported Santos to modernize its surveillance and optimization workflows while significantly reducing the time and effort required from engineering teams.

“IPSM represents a fundamental shift in how production systems are understood and optimized,” said Sanjay Paranji, CEO of Xecta. “By combining domain physics with AI, IPSM enables a continuously calibrated view of field performance at scale—automating surveillance, surfacing optimization opportunities, and dramatically reducing manual effort in even the most complex environments.”

Spacely Media is proud to unveil the beta launch of its revolutionary platform, Spacely:Transact for Print, officially launched on April 28, 2025. This pioneering marketplace fuses the enduring influence of print media with the streamlined efficiency of digital technology, marking a transformative shift in how print advertising space is traded.

Launching with just over $100 million in contracted gross merchandise value (GMV), Spacely:Transact for Print positions itself as a game-changing innovation in the media buying landscape.

The platform fundamentally reshapes the industry by eliminating friction points traditionally associated with print advertising transactions. Advertisers and publishers now have unprecedented access to a centralized, intuitive platform designed specifically to simplify the procurement and sale of print media. This groundbreaking approach leverages digital efficiency while amplifying the tangible impact of print advertising, delivering unmatched value for media professionals.

Already embraced by many publishers, from national giants to influential regional and niche local titles, as well as renowned global publications, Spacely:Transact underscores the widespread appetite for enhanced transaction efficiency and marketplace transparency. Its rapid industry adoption signals a new era in print media commerce, responding directly to the evolving demands of today's integrated advertising landscape.

David Coker, CEO of Spacely, commented, “Spacely:Transact for Print is more than just an evolution; it’s a revolution in the media marketplace. Our vision was to seamlessly merge print’s undeniable influence with digital’s agility and transparency, and we're thrilled to see this vision realized. We’re committed to continuously innovating, empowering our partners, and driving significant advancement within the premium offline media ecosystem.”

Looking forward, Spacely is dedicated to expanding its suite of products and enhancing platform capabilities, including deeper integration with out-of-home (OOH) and sponsorship media. The company remains at the vanguard of marketplace innovation, setting new standards for integrated media transactions.

For more information about Spacely and to explore how its innovative solutions can enhance your media strategies, visit spacely.media.

SKYX Platforms Corp. (NASDAQ: SKYX), a smart home technology leader with over 100 issued and pending patents globally, announced a global sales and marketing collaboration agreement with Parrot Uncle, a world-leading manufacturer of ceiling fans and home décor products. The agreement will support the U.S. and international rollout of SKYX’s new all-in-one smart turbo heater and ceiling fan, along with other patented plug-and-play smart home technologies.

Parrot Uncle, which has sold millions of ceiling fans in the U.S. and global markets, will partner with SKYX to bring this innovative multi-functional product to a broad consumer and commercial audience. The product line launch is scheduled for the third quarter of 2025, aligned with the upcoming winter season.

The SMART SkyFan, which combines a ceiling fan, heater, and light into a single smart fixture, is being produced in multiple versions and available in 6 to 8 color options to meet diverse residential and commercial demands. Production is currently underway with SKYX’s manufacturing partners.

The ceiling fan and space heater category represents a multi-billion-dollar annual market, with tens of millions of units sold in the U.S. alone. SKYX anticipates that the successful launch of this product line will be a major milestone toward achieving cash-flow positive operations in 2025.

“This sales and collaboration agreement with Parrot Uncle is strategic for both U.S. and global markets,” said Rani Kohen, founder and executive chairman of SKYX Platforms Corp. “This exemplifies our commitment to global strategic relationships based on our innovation, safety, and global market products. As we prepare for our upcoming launch, we believe this breakthrough all-in-one heater ceiling fan solution will drive significant value for our customers, partners, and shareholders.”

The SMART SkyFan, Heater & Light is designed to provide efficient, all-season comfort in a smart, easy-to-install format, supporting SKYX’s mission to make homes and buildings smarter, safer, and more advanced.

To see SKYX’s technologies in action, click here.

About SKYX Platforms Corp.

As electricity is a standard in every home and building, our mission is to make homes and buildings become safe-advanced and smart as the new standard. SKYX has a series of highly disruptive advanced-safe-smart platform technologies, with over 100 U.S. and global patents and patent pending applications. Additionally, the Company owns over 60 lighting and home decor websites for both retail and commercial segments. Our technologies place an emphasis on high quality and ease of use, while significantly enhancing both safety and lifestyle in homes and buildings. We believe that our products are a necessity in every room in both homes and other buildings in the U.S. and globally. For more information, please visit our website at www.skyplug.com or follow us on LinkedIn.

Forward-Looking Statements

Certain statements made in this press release are not based on historical facts, but are forward-looking statements. These statements can be identified by the use of forward-looking terminology such as “aim,” “anticipate,” “believe,” “can,” “could,” “continue,” “estimate,” “expect,” “evaluate,” “forecast,” “guidance,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “outlook,” “plan,” “potential,” “predict,” “probable,” “project,” “seek,” “should,” “target” “view,” “will,” or “would,” or the negative thereof or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These statements reflect the Company’s reasonable judgment with respect to future events and are subject to risks, uncertainties and other factors, many of which have outcomes difficult to predict and may be outside our control, that could cause actual results or outcomes to differ materially from those in the forward-looking statements. Such risks and uncertainties include statements relating to the Company’s ability to successfully launch, commercialize, develop additional features and achieve market acceptance of its products and technologies and integrate its products and technologies with third-party platforms or technologies; the Company’s efforts and ability to drive the adoption of its products and technologies as a standard feature, including their use in homes, hotels, offices and cruise ships; the Company’s ability to capture market share; the Company’s estimates of its potential addressable market and demand for its products and technologies; the Company’s ability to raise additional capital to support its operations as needed, which may not be available on acceptable terms or at all; the Company’s ability to continue as a going concern; the Company’s ability to execute on any sales and licensing or other strategic opportunities; the possibility that any of the Company’s products will become National Electrical Code (NEC)-code or otherwise code mandatory in any jurisdiction, or that any of the Company’s current or future products or technologies will be adopted by any state, country, or municipality, within any specific timeframe or at all; risks arising from mergers, acquisitions, joint ventures and other collaborations; the Company’s ability to attract and retain key executives and qualified personnel; guidance provided by management, which may differ from the Company’s actual operating results; the potential impact of unstable market and economic conditions on the Company’s business, financial condition, and stock price; and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including its periodic reports on Form 10-K and Form 10-Q. There can be no assurance as to any of the foregoing matters.

Any forward-looking statement speaks only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by U.S. federal securities laws.

Celesta Capital, a leading global deep tech venture capital firm, today announced two key leadership appointments to further reinforce its team and advance startups driving pioneering scientific and engineering breakthroughs. Matthew Marsh has been elevated to general partner, while Robin Clewley has been appointed partner and will lead investor relations.

“These appointments underscore Celesta’s commitment to building our team, fostering exceptional growth, and enabling transformative outcomes for our investors and portfolio companies,” said Nicholas Brathwaite, founding managing partner at Celesta. “Matt has consistently delivered operational excellence and strategic vision, while Robin’s deep expertise in marketing, along with a track record for cultivating strong relationships with customers and partners, perfectly positions her to fortify our global network. Their combined leadership will advance the firm’s mission to support the next generation of groundbreaking deep tech companies.”

Marsh, who joined Celesta Capital as CFO in 2020, brings over 25 years of global, diverse experience in technology businesses, across consumer, healthcare, building materials, and B2B technology. In his expanded role, Marsh will continue his oversight of the CFO office, while engaging more deeply with Celesta’s existing portfolio and new investment deals.

Prior to Celesta, Marsh served as CFO and executive vice president at James Hardie Industries, and held multiple leadership roles at GE, including CFO positions within GE Healthcare’s IT business and U.S. Healthcare Systems divisions. His international experience spans over 30 countries.

“I’m honored and energized by this new role at such a pivotal moment for deep tech innovation,” said Marsh. “Celesta is uniquely positioned to leverage the historic wave of technology acceleration unlocked by the AI boom. I look forward to deepening my collaboration with our world-class ecosystem to help build companies that will shape the future.”

Clewley, a seasoned marketing and investment professional, brings more than two decades of experience across multiple sectors and global organizations, including the Gates Foundation, and sits on multiple Celesta portfolio company boards. Having previously served as advisor and chief marketing officer for Celesta, she will spearhead investor engagement initiatives in her new role, while also supporting and leading investment deals.

“I’m thrilled to lead the firm’s efforts in building enduring investor partnerships, while continuing to support our portfolio,” said Clewley. “It’s an extraordinary time for deep tech investing, and I am eager to continue expanding Celesta’s global network of limited partners who share our passion about transformative technologies.”

Deep tech has surged from an estimated 10% of venture capital investment in the early 2010s, doubling to more than 20% today, according to BCG. Multiple projections estimate the deep tech market will grow at a rate of 12–15% over the next decade, driven by escalating demand for AI hardware solutions and the expansive range of emerging AI applications.

These new appointments follow recent additions bolstering the Celesta team, including former General Catalyst partner and noted seed investor Anand Chandrasekaran as managing partner; Charles Lespérance as the firm’s inaugural partner based in emerging deep team market Canada; and Nobel Laureate Dr. James Rothman as senior advisor.

Camron Dowlatshahi, partner at MSD Lawyers, today shared insights on how to navigate California's employment law landscape, one of the most dynamic and complex in the United States. Staying informed about these regulations is not just a matter of best practice but a legal necessity for employers and employees. Navigating this intricate web requires a comprehensive understanding of state mandates, ranging from wage and hour laws to anti-discrimination statutes.

Compliance is paramount for all businesses operating in the Golden State to avoid legal pitfalls and foster a positive work environment. Employees must also know their rights and protections under these laws to ensure rightful and fair treatment so they can advocate for themselves when necessary.

Key Aspects of California Employment Law

California employment law is unique due to its progressive nature and robust employee protections. Unlike federal law, which sets a baseline, California often goes further to safeguard workers' rights.

For example, California's minimum wage consistently exceeds the federal level, and the state provides more expansive leave entitlements. These differences highlight the importance of focusing specifically on California law for anyone working or employing individuals within the state.

Employers must be vigilant to ensure their current policies and practices align with these stringent state requirements, as non-compliance or complacency can lead to significant legal, reputational, and financial repercussions. Employees also benefit from understanding these enhanced protections, empowering them to recognize and address workplace violations.

Minimum Wage

Effective January 1, 2025, the new mandated minimum wage for all employers is $16.50 per hour. Additionally, fast food workers will earn $20.00 per hour starting April 1, 2024, under AB 1228. Certain healthcare workers earn between $18 and $25+ per hour in phases under SB 525. These sector-specific increases underscore the state’s ongoing efforts to address wage equity across industries.

Employee Protections

California offers broad employee protections through the Fair Employment and Housing Act (FEHA), which is now enforced by the California Civil Rights Department (CRD). FEHA covers various employment practices, including anti-discrimination, retaliation, and wrongful termination safeguards, ensuring that workers are treated fairly regardless of their status, background, or identity.

Leave Entitlements

California provides more generous leave entitlements than those required under federal law. For instance, SB 616 expands paid sick leave to five days or 40 hours annually. Additional leave provisions exist for circumstances such as family care, pregnancy, and issues related to domestic violence.

Retaliation Protections

Employees in California are legally protected from retaliation when they report workplace misconduct. This includes retaliation for reporting discrimination, harassment, unsafe working conditions, and wage violations or exercising their rights under various leave laws. These protections are critical to ensure employees can speak out without fear or danger of losing their jobs.

Wrongful Termination Protections Under FEHA

California's Fair Employment and Housing Act (FEHA), now administered by the Civil Rights Department (CRD), is a cornerstone of employee protection against discrimination, harassment, and retaliatory termination. 

FEHA prohibits employers from wrongfully terminating employees based on several protected characteristics, ensuring a workplace free from bias. Protected categories include race, color, national origin, ancestry, sex, gender identity, sexual orientation, disability, medical condition, genetic information, pregnancy, religion, age (over 40), marital status, and more.

California is an at-will employment state; hence, employers can terminate employees without cause, provided the reason is not illegal. However, FEHA offers essential limits for this doctrine. Discriminatory or retaliatory terminations are unlawful, and protections also extend to employees engaging in protected activities such as filing complaints or participating in lawful investigations.

California law further recognizes "implied contracts," meaning that employer actions or assurances may create a reasonable expectation of continued employment, even absent a written contract. 

Additionally, the Private Attorneys General Act (PAGA) allows employees to rightfully file lawsuits on behalf of themselves and others for Labor Code violations, which may arise after reporting wrongful termination or other workplace misconduct, reflecting the state's strong commitment to labor rights enforcement.

Expanded Protections: Cannabis, Intersectionality, and Safety

As of January 1, 2024, under AB 2188, California prohibits employers from discriminating against their employees for off-duty cannabis use, provided it does not impair performance or safety-sensitive duties. Exceptions apply to federal contractors and safety-related roles.

FEHA already protects against discrimination based on multiple overlapping characteristics (intersectionality), and recent CRD enforcement emphasizes this.

Meanwhile, SB 553 (2023) requires California employers to implement written workplace violence prevention plans by July 1, 2024, highlighting a new era of proactive safety in employment law.

Reimbursement and Remote Work

California Labor Code §2802 requires all the state's employers to reimburse their employees for incurred necessary business expenses. For remote workers, this includes partial reimbursement of internet and phone expenses if essential for work. 

Resources for Employers and Employees

Employers can access compliance resources from the California Chamber of Commerce and use HR management software like Gusto to automate payroll, track labor law updates, and maintain accurate employee records. The Society for Human Resource Management's (SHRM's) study notes that integrating HR tech can reduce compliance violations by up to 20 percent.

For up-to-date guidance, employees should consult the official channels of the California Department of Industrial Relations (DIR) and the California Civil Rights Department (CRD) websites. Legal aid organizations provide support to workers facing wrongful termination or wage violations. Employees facing discrimination or retaliation should consult employment law attorneys early to understand their options.

Stay Compliant and Empowered: Your Next Steps in California Employment Law

California's employment laws are comprehensive and strongly favor employee protection, requiring careful attention from employers and workers. Understanding key factors such as wrongful termination protections under FEHA, minimum wage obligations, leave entitlements, expense reimbursements, and new safety mandates is essential to maintaining compliance.

Now is the time to assess your workplace policies, update your employee handbooks, and consult with qualified legal counsel to ensure you're compliant and prepared for what's ahead. You can foster a compliant, equitable, and safe workplace by utilizing available tools and staying informed on legislative changes. Staying proactive is the best strategy to thrive in California's dynamic legal environment.

GG.BET is pleased to announce that it is now the official partner of Usyk vs. Dubois II, the bout for the title of undisputed heavyweight champion of the world. For the first time in the history of heavyweight boxing, the fight will be sponsored by a betting brand with Ukrainian roots. The bout will take place on July 19 at Wembley Stadium in London. The current WBA, WBO, WBC, and IBO champion Oleksandr Usyk will face IBF titleholder Daniel Dubois.

This will be the second fight between Usyk and Dubois. Their first bout took place in August 2023 in Poland, where the Ukrainian won by technical knockout. The rematch holds special significance for Dubois, as it will take place at the world-renowned arena in his home city. For Usyk, it’s another chance to reaffirm his dominance, making this bout a potentially legendary global sporting event.

GG.BET has partnered with Queensberry Promotions and Ready to Fight for this historic event. The cooperation includes full integration of visual elements of the GG.BET brand across key parts of the ring, as well as brand presence in promotional materials and during major event moments: the press conference on July 17, the weigh-in on July 18, and the fight itself. Boxing fans will also be able to take part in special activities and giveaways from GG.BET on social media and get special offers for the fight on the bookmaker’s website.

“We didn’t choose the slogan ‘Big fight. Real thrills.’ for this event by chance. It perfectly reflects both the scale of the event itself and the excitement viewers can experience. We are proud to be part of such a historic event and hope every viewer will enjoy the fight to the max,” commented the GG.BET press office.

The betting brand is well-known for supporting major esports events. GG.BET has served as the official sponsor of top-tier tournaments such as the BLAST Premier CS2 series, Dota 2’s The International 2022, and many others. The brand is now expanding its focus into traditional sports and actively supports professional teams and events.